Cell Source, Inc.
CLCS · OTCMCIK 1569340fmd_0MAZ9JR09E1GXWXY72MMEMMWBJManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jul 01, 2012 to Mar 31, 2025, 50 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | 0 | 1 | 1 | 0 | 2 | 1 | 1 | 2 | – | – |
| Selling, general and administrative | 1 | 1 | 1 | 1 | – | – | – | – | – | – |
| Total operating expenses | 2 | 2 | 2 | 2 | 4 | 4 | 4 | 4 | 4 | 4 |
| Operating income | – | – | (2) | (2) | (4) | (4) | (4) | (4) | (4) | (4) |
| Interest expense | 0 | 0 | 0 | (0) | 0 | 0 | 1 | – | – | – |
| Other non-operating income (expense) | (0) | 1 | (1) | (0) | (1) | (1) | (1) | (1) | (1) | (1) |
| Income before taxes | (3) | (1) | (3) | (2) | (4) | (5) | (5) | (5) | (5) | (5) |
| Income tax expense | 0 | 0 | 0 | – | 0 | 0 | – | – | – | – |
| Net income from continuing operations | (2) | (2) | (2) | – | (4) | (5) | – | – | – | – |
| Net income | (3) | (1) | (3) | (2) | (4) | (5) | (5) | (5) | (5) | (5) |
| Net income to common shareholders | – | – | – | (3) | (5) | (5) | (6) | (6) | (7) | (6) |